Leaders in Humoral Immuno-Oncology

Translating clinical knowledge into innovation

previous arrowprevious arrow
next arrownext arrow

our mission

We are leading the way in Humoral Immuno-Oncology (HIO) by uncovering tumors producing HIO-factors that suppress responses of immune-mediated anti-cancer therapies. We accomplish our mission by developing therapeutic agents that can overcome the immunosuppressive effects of HIO-factors as well as by developing diagnostic assays that can identify patients with tumors producing HIO-factors to advise physicians on therapeutic options


Chief Executive Officer

CEO & co-founder. Former CEO & co-founder of Morphotek. Ph.D. in Human Genetics, Thomas Jefferson University

Chief Scientific Officer

CSO & co-founder. Former VP, CSO and co-founder of Morphotek. Ph.D. in Pathology, University of Catania, Italy

VP Financing

VP of Finance and Operations. Former Executive Director of Accounting at Morphotek. B.S. in Accounting, West Chester University

Sen. Director of R&D

Sen. Director of R&D. Former Director of Antibody Development at Morphotek. Ph.D. in Microbiology and Immunology, University of Miami.

What the experts say about us

News & Events

Collaborative Environment

For inquiries or to request additional information, we can be reached by email or calling our corporate headquarters

Navrogen Inc

1837 University Cir.
Science Center Room 218
Cheyney PA 19319

Investor Relations

Steve Kyriakos
+1(610) 399-2717

General Information

- Media inquiries
- Career inquiries